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We evaluated empirically the performance of various methods of calculating age-adjusted survival estimates when age-specific data
are sparse. We have illustrated that a recently proposed alternative method of age adjustment involving the use of balanced age
groups or age truncation may be useful for enhancing calculability and reliability of adjusted survival estimates.
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Age adjustment is widely used in studies comparing survival of
different cancer patient populations. Most commonly, the
comparison is made by calculating a weighted average of age-
specific survival estimates, using weights reflecting the age
distribution of some defined standard population. There has,
however, been a large diversity in the practice of age adjustment,
mainly concerning the definition, the number and width of the age
groups, and methods to overcome difficulties when the age-
specific survival could not be calculated. Such situations are not
uncommon in comparative survival studies, particularly when data
for rare cancers or data from registries covering smaller
populations is involved. Examples of the practice of age
adjustment of cancer survival are given in Table 1.
Recently, an alternative method was proposed for age adjust-
ment of survival estimates (Brenner et al, 2004), in which weights
are assigned to the patients before one carries out the survival
analysis. Weights are determined as the percentage of patients in
the age group the patient belongs to in the standard population
divided by the corresponding percentage in the study population.
Survival analysis is carried out using the weighted individual data,
without the need to calculate age-specific survival estimates
(Brenner et al, 2004).
In this paper, we empirically evaluate and compare the
performance of different options of age adjustment methods in
situations when age-specific data are sparse.
MATERIALS AND METHODS
Data set
Data from the Zimbabwe National Cancer Registry (ZNCR)
(Chokunonga et al, 2000; Parkin et al, 2003) were used. The
registry, established in 1985, covers the population of the
Zimbabwean capital, Harare. In terms of operational circum-
stances, which have been described in detail elsewhere, the registry
may be considered as a typical example for an urban developing
country cancer registry with appropriate data quality outcomes
(Sankaranarayanan et al, 1998; Parkin et al, 2003; Chokunonga
et al, 2004). Survival results for a large number of cancer sites were
recently published elsewhere (Gondos et al, 2004).
We assessed various options of age adjustment of 5-year
survival estimates among patients diagnosed with five different
types of cancers in 1993–1997 and followed up until 31 December
1999: skin melanomas, breast, cervical and prostate cancer and
lymphomas. Breast and cervical cancers were included because
they were represented by relatively large samples. Prostate cancer,
for which only 3-year survival could be calculated due to the lack
of patients with a 5-year follow-up time, was included because of
the unusual age distribution (high proportions of older patients).
Lymphomas were included because of the uniquely wide age range
of the patients, and skin melanomas were selected as an example of
an analysis with a very small sample.
Calculation of age-adjusted survival
The site-specific World Standard Cancer Patient Populations
(WSCPP) were used as standard populations (Black and Bashir,
1998). Adjustment of the survival estimates was carried out
according to the traditional method, and the alternative method
recently proposed by Brenner et al (2004), using the age
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ycategorisation schemes described below. Throughout this paper,
relative rather than absolute survival estimates are presented.
The relative survival estimates were calculated according to
Hakulinen’s method (Hakulinen, 1982), using the WHO life tables
for Zimbabwe (WHO, 2001). The calculations were carried out
using the SAS macros periodh (Brenner et al, 2002) and
adperiodh (Brenner et al, 2004).
Scheme 1: Age adjustment with fixed age group width
First, for each cancer site, we classified the patients by 5-, 10-, 15-
and 30-year age groups. With each of these classifications, both the
youngest and the oldest age groups were selected so that they
actually included patients, and the age of the youngest/oldest
patient determined the first/last age group (eg, if the youngest
Table 1 Examples of age adjustment of population-based cancer survival estimates in the recent literature
Authors (year) Study/registry Cancer sites Age groups (years) Standard population Note
Aareleid et al
(1998)
EUROCARE-2 Testicular cancer 15–44, 45–54, 55–64, 65–
74, 75+
All cases with malignant testicular
cancer included in the study, in
addition time-series comparison
using EUROCARE-1
Age adjustment often failed
Sant et al (1998) EUROCARE-2 Malignant brain
tumours
15–44, 45–54, 55–64, 65–99 All cases with malignant brain
tumours included in the study
Age adjustment often failed
Sant et al (2001) EUROCARE-2 10+ different sites 15–44, 45–54, 55–64, 65–99 All cases included in the study, by
site
Capocaccia et al
(2003)
EUROCARE-3 10+ different sites 15–44, 45–54, 55–64, 65–
74, 75+
All cases included in the study, by
site
Missing age-specific values
modelled
Dickman et al
(1999)
Finland 10+ different sites 0–14, 15–29, 30–44, 45–59,
60–74, 75+
Cancer patient populations of the
most recent period in the study
(1985–1994)
Sankaranarayanan
et al (1998)
IARC: Cancer survival
in developing countries
10+ different sites 0–34, 35–44, 45–54, 55–64,
65–74, 75+
World Standard Cancer Patient
Populations
Age groups were collapsed
when age-specific survival
could not be calculated,
additional analyses for
truncated age range 0–74
years
Wang et al (2003) Singapore Cervical cancer 0–39, 40–49, 50–59, 60–69,
70+
World Standard Cancer Patient
Populations
Chokunonga et al
(2004)
ZNCR Cervical Cancer 0–34, 35–44, 45–54, 55–64,
65–74, 75+
World Standard Cancer Patient
Populations
IARC¼International Agency for Research on Cancer, Lyon, France; ZNCR¼Zimbabwe National Cancer Registry, Harare.
Table 2 Age distributions of cancer patient populations in Zimbabwe and of the WSCCP, and the calculability of age specific 5-year survival estimates, by
5-year age groups
Skin melanoma Breast Cervix Prostate Lymphomas
Zimbabwe
WSCCP
Zimbabwe
WSCCP
Zimbabwe
WSCCP
Zimbabwe
WSCCP
Zimbabwe
WSCCP
Age group (years) N % F
a % N % F
a % N % F
a % N % F
a % N % F
a %
0–4 — 0 0 — 0 0 — 0 0 — 0 0 4 3.4 2.8
5–9 — 0 0.1 — 0 0 — 0 0 — 0 0 5 4.2 w 2.7
10–14 — 0 0.4 — 0 0.1 — 0 0.1 — 0 0 6 5.1 2.7
15–19 — 0 0.9 — 0 0.3 — 0 0.3 — 0 0 5 4.2 w 2.8
20–24 — 0 1.8 5 4.4 w 0.9 1 0.4 w 1.1 — 0 0 5 4.2 3.1
25–29 2 4.9 w 3.3 2 1.8 2.1 14 6.0 2.7 — 0 0 13 11.0 3.5
30–34 3 7.3 4.9 5 4.4 4 26 11.2 5.2 — 0 0.1 17 14.4 4
35–39 2 4.9 6.6 20 17.5 6.4 27 11.6 8.2 — 0 0.2 18 15.3 4.6
40–44 2 4.9 7.8 13 11.4 8.5 32 13.8 10.8 — 0 0.3 16 13.6 5.4
45–49 7 17.1 8.7 20 17.5 10 36 15.5 12.1 — 0 0.8 11 9.3 6.2
50–54 4 9.8 9 13 11.4 10.5 24 10.3 12 2 5.7 1.6 7 5.9 w 7
55–59 6 14.6 8.9 11 9.7 10.2 24 10.3 10.9 2 5.7 3.3 6 5.1 7.7
60–64 6 14.6 9.1 14 12.3 9.7 21 9.1 9.8 8 22.9 6.2 3 2.5 w 8.5
65–69 6 14.6 8.7 3 2.6 9 12 5.2 w 8 6 17.1 8.7 0 0 8.4
70–74 0 0.0 8.3 2 1.8 8.2 9 3.9 6.5 7 20.0 12.1 1 0.9 8.2
75–79 2 4.9 7.8 6 5.3 7.5 4 1.7 w 5.2 6 17.1 16.4 0 0 7.9
80–84 1 2.4 7.2 — 0 6.7 1 0.4 4.1 1 2.9 21.8 0 0 7.5
85+ — 0 6.5 — 0 5.9 1 0.4 w 3 3 8.6 28.5 1 0.9 w 7
Total 41 114 232 35 118
WSCCP¼World Standard Cancer Patient Population.
aF(ailure): Crosses (w) indicate that the age-specific survival estimate for the 5th year could not be calculated in an age
group that was otherwise not empty.
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ypatient was 28, the first 5/10/15/30-year age group was 25–29/20–
29/15–29/0–29, respectively).
Scheme 2: Collapsing the youngest and oldest age groups
If needed, that is, if the age adjustment failed, we applied
modifications to the boundaries of the youngest and the oldest
age groups to enhance calculability: the boundaries of these age
groups were modified so that the age-specific survival in these
(youngest and oldest) age groups could be calculated. Age groups
in between were left unchanged, except for the 30-year age groups,
where the shifting of the first or last age group affected the middle
age group as well.
Scheme 3: Balanced age groups
Here, we reorganised the age groups in such a way that the number
of observations in the age groups would be approximately evenly
distributed. The number of age groups was varied between 3 and 5.
The boundaries of these ‘balanced’ age groups were aligned to the
nearest of those of the original 5-year age groups.
Calculation of truncated survival
Age-specific survival estimates are often unreliable for older
age groups in data from developing countries. Often, as is the
case in our study, the standard population gives more weight to
the oldest age group than does the study population. In these
cases, the adjusted survival estimate can easily become unreliable,
as the adjustment assigns a large weight to an unreliable
age-specific survival estimate. We therefore repeated all
calculations with a truncated age range (0–74 years),
following the practice in the so far largest comparative
survival study from developing countries (Sankaranarayanan
et al, 1998).
RESULTS
Table 2 shows the numbers of patients by age group in the
Zimbabwean cancer populations, illustrates the differences be-
tween the age distributions of the study and the standard
populations, and indicates the age groups for which the 5-year
age-specific survival estimate could not be calculated. The WSCPP
include a much higher proportion of patients in the oldest 2–4 age
groups than the Zimbabwean patient populations.
Table 3a provides survival estimates adjusted by the
traditional and the alternative method, with all ages included,
according to the different schemes we applied. With the
traditional method, the fixed age group classifications often
failed, due to a failure in calculating 5-year age-specific
survival estimates. With collapsed or balanced age groups, the
traditional age adjustment became feasible in most cases. The
alternative method was feasible even with most fixed age
group categorisations, except for the 5-year categories for skin
melanomas and lymphomas, where one age group was empty
and therefore the weight to be assigned to the patients in the
age group could not be calculated. With both the traditional
and the alternative method, the application of different age groups
resulted in different adjusted survival estimates for all cancer types
studied. With the use of balanced age groups, variation was
strongly reduced.
Table 3b summarises and compares the results obtained
by calculating adjusted survival estimates with all ages
involved and with truncated cancer patient populations.
The truncation did not alter the crude survival estimates
significantly: the differences between the crude and the truncated
crude survival estimates were between 0.6 and 3.6% units.
However, the variation in the adjusted survival estimates among
the different categorisation schemes was strongly reduced for all
cancer sites.
DISCUSSION
With the traditional method, the calculation of 5-year age-specific
survival estimates often failed in age groups with a few patients
only. Failures could mostly be overcome by the application of
different age categorisation schemes, that is, by collapsing or
balancing the age groups. When using the alternative method
(Brenner et al, 2004), calculability was generally very good, even
with the fixed age group categorisation schemes.
However, with both methods, the different age group classifica-
tions produced age-adjusted estimates with a rather large
variability, mainly because of the assignment of large weights for
the older age groups in which data were sparse in the ZNCR. These
variations could be effectively reduced using balanced age groups
and by restricting the analysis to a truncated age range up to 74
years.
There is no theoretically best practice with regard to the
number of age groups, their width and the boundaries of
the individual age group classifications. For practical purposes,
however, adjusted estimates should be reasonably consistent,
no matter what age classifications are used. Limitations in
data quality frequently impair the reliability of age-specific
data among older patients, particularly in case of patient
populations from developing countries (Sankaranarayanan et al,
1998). In such cases, the calculation of truncated adjusted
survival may provide estimates of improved reliability and
comparability. On the other hand, truncation means that
the survival experience of older patients is neglected, which
would be justified only if the proportion of these patients is very
small. The use of balanced age groups is not affected by this
limitation and may be preferred if the exclusion of older patients is
of concern.
In looking at the results, the following limitations should be kept
in mind. Our empirical evaluation is based on five cancer sites
from one cancer registry only. The cancer sites were chosen to
represent various sample sizes, age distributions, and higher and
lower survival patterns, and therefore reflect a variety of scenarios
encountered in comparative analyses of survival. While the
problems of sparseness of data and discrepancy between the age
distribution of the study population and the standard population
were probably more extreme than in most other practical
applications, such extreme data situations may facilitate the
demonstration of the implications of various analysis strategies
under the above conditions. We did not include standard errors of
survival estimates obtained with the various methods. As recently
demonstrated elsewhere (Brenner and Hakulinen, 2005), the
alternative method often provides estimates with a smaller
standard error.
In summary, our results on the one hand illustrate that the
enhanced calculability of age-adjusted survival estimates by the
alternative method may be relevant in practice. Nevertheless, the
unreliability of estimates in case of sparse data within age groups
may remain a concern for both the traditional and the alternative
method. In such situations, the use of balanced age groups or the
calculation of truncated age-adjusted survival estimates may be
useful analytical options.
ACKNOWLEDGEMENTS
This work was supported in part by the German Research
Foundation (Deutsche Forschungsgemeinschaft, Graduiertenkolleg
793).
Calculating age-adjusted survival when data are sparse
A Gondos et al
452
British Journal of Cancer (2006) 94(3), 450–454 & 2006 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yTable 3 (a) The 5-year relative survival (in %) of Zimbabwean cancer patients, adjusted to WSCPP and (b) summary of calculating truncated survival estimates: differences in the crude estimates, and
ranges of the adjusted survival estimates for all ages and truncated cancer patient populations
Skin melanoma Breast Cervix Prostate (3 years survival) Lymphomas
(a) 5 year relative survival (in %) of Zimbabwean cancer patients, adjusted to WSCPP
Crude relative survival 49.9 37.9 30.5 27.1 23.1
Age-adjusted survival Traditional
method
Alternative
method
Traditional
method
Alternative
method
Traditional
method
Alternative
method
Traditional
method
Alternative
method
Traditional
method
Alternative
method
Fixed age group width (years)
5 —* — — 48.1 — 32.5 46.3 45.6 — —
10 — 40.9 54.1 46.2 — 31.2 39.6 33.8 — 37.5
15 — 44.6 51.3 43.1 — 31.2 21.1 21.5 — 48.6
30 — 49.2 38.3 38.9 30.0 29.1 26.8 26.9 — 39.9
Collapsed age group width (years)
5 — 44.9 56.6 48.1
a 34.0 32.5
a 46.3
a 45.6
a — 38.0
10 37.3 40.9
a 54.1
a 46.2
a 36.0 31.2
a 39.6
a 33.8
a 18.2 37.5
a
15 41.5 44.6
a 51.3
a 43.1
a 29.9 31.2
a 21.1
a 21.5
a 23.9 48.6
a
30 49.3 49.2
a 38.3
a 38.9
a 30.0
a 29.1
a 26.8
a 26.9
a 23.7 39.9
a
Balanced age groups
5 age groups 41.6 43.0 39.1 39.2 29.3 28.7 21.3 21.9 — 28.3
4 age groups 41.4 43.1 38.7 39.0 29.9 29.5 21.3 21.8 24.6 24.6
3 age groups 48.0 48.8 36.1 35.4 27.6 28.7 21.4 21.7 17.7 17.9
Summary Skin melanoma Breast Cervix Prostate (3 years survival) Lymphomas
(b) Summary of calculating truncated survival estimates: differences in the crude estimates, and ranges of the adjusted survival estimates for all ages and truncated cancer patient populations
Difference between all age
and truncated crude relative
survival
 2.6 2.2 0.6  3.6 0.6
Range (highest–lowest) of
adjusted survival estimates
Traditional
method
Alternative
method
Traditional
method
Alternative
method
Traditional
method
Alternative
method
Traditional
method
Alternative
method
Traditional
method
Alternative
method
All ages 12.0 8.2 20.5 12.7 8.4 3.8 25.2 24.1 6.9 30.7
Truncated 4.2 4.5 6.6 4.8 4.5 1.9 0.9 1.5 5.6 12.7
WSCCP¼World Standard Cancer Patient Population.
aValues are the same as in the fixed age group analysis, as there was no need to collapse age groups. *Age specific survival could not be calculated.
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